Three-Year Data Demonstrate Sustained Reduction in Gastrointestinal Toxicity with Barrigel\u2122 Rectal Spacer2<\/sup><\/i><\/p>\n WAYNE, Pa.–(BUSINESS WIRE<\/a>)– \nIn parallel with Teleflex\u2019s long-term strategy to significantly streamline the Teleflex business and narrow focus to the critical care and high-acuity hospital end-markets, the company\u2019s Interventional Urology business unit continues to drive clinical value as it prepares for its divestiture in the second half of 2026.<\/p>\n \nData presented at the 2026 American Urological Association (AUA) Annual Meeting in Washington, DC. May 15 \u2013 18 and the European Society for Radiotherapy & Oncology (ESTRO) Congress held in Stockholm May 15 \u2013 19 highlight early patient experience following BPH treatment1<\/sup> with the UroLift\u2122 System and sustained reductions in radiation-associated toxicity for prostate cancer patients who received Barrigel\u2122 rectal spacer.2<\/sup><\/p>\n CLEAR RCT: First Head-to-Head Comparison of Minimally Invasive Surgical Therapies (MISTs) Demonstrates Favorable Early Patient Experience with the UroLift\u2122 System*<\/b><\/p>\n \nAt AUA 2026, Dr. Bilal Chughtai**, a urologist with Northwell Health, Garden City, N.Y., presented 12-month findings from the CLEAR (Comparing UroLift\u2122 Experience Against Rez\u016bm\u2122) randomized controlled trial, the first prospective, multicenter, head-to-head RCT comparing MISTs for BPH.1<\/sup><\/p>\n \nThe study evaluated key endpoints including catheter independence, symptom improvement, patient experience, and sexual function.1<\/sup><\/p>\n \nKey study endpoints of the study:<\/p>\n \n\u201cWhat stands out in our CLEAR RCT study is the consistency of the early patient experience advantages with the UroLift\u2122 System, particularly catheter independence, rapid recovery, and preservation of sexual function, which are critical factors for both patients and physicians when selecting a treatment approach,\u201d said Dr. Bilal Chughtai**, a urologist practicing in Syosset, N.Y.<\/p>\n Barrigel\u2122 Rectal Spacer Three-Year Data Demonstrate Sustained Reduction in Radiation-Associated Toxicity*<\/b><\/p>\n \nAt ESTRO 2026, new three-year outcomes presented by Dr. Martin King** highlighted the long-term safety and effectiveness of Barrigel\u2122 rectal spacer.2<\/sup><\/p>\n \nKey endpoints of the study:<\/p>\n \nThese results demonstrate a durable benefit for the Barrigel\u2122 rectal spacer subjects sustained through three years, reinforcing the role of rectal spacing in protecting bowel function during and after radiation therapy.2<\/sup><\/p>\n \n\u201cThe three-year data further validate the clinical value of Barrigel\u2122 rectal spacer, demonstrating sustained and clinically meaningful reductions in gastrointestinal toxicity,\u201d said Martin King**, MD, PhD, presenter and radiation oncologist with the Dana-Farber Brigham Cancer Center, Harvard Medical School Associate Professor of Radiation Oncology. \u201cReducing radiation treatment-related toxicity is essential for prostate cancer patients, and these findings support the continued adoption of rectal spacing as a standard component of care.\u201d 2<\/sup><\/p>\n \n\u201cThese data reflect our prostate health leadership and ongoing commitment to advancing evidence-based, patient-centered solutions across the urology care continuum,\u201d said Travis Gay, President and General Manager, Interventional Urology, Teleflex. \u201cFrom improving early recovery and preserving sexual function in BPH patients with the UroLift\u2122 System to delivering durable protection against radiation-related rectal toxicity with Barrigel\u2122 spacer, we are focused on technologies that meaningfully improve patients\u2019 lives.\u201d<\/p>\n About the UroLift\u2122 System UroLift System Important Safety Information About Barrigel\u2122<\/strong>Rectal Spacer \nHyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.13,14<\/sup><\/p>\n \nBarrigel\u2122 rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy11<\/sup> and is cleared for rectal spacing in the United States, Australia, and Europe.15 <\/sup>Barrigel\u2122 rectal spacer is indicated for prostate cancer patients with T1-T3b disease. For more information about Barrigel\u2122 rectal spacer, please visit https:\/\/barrigel.com\/hcp\/barrigel-control-matters<\/a>.<\/p>\n Barrigel\u2122 Rectal Spacer Important Safety Information \nIt should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital\/pelvic area.<\/p>\n \nPotential complications include but are not limited to: pain associated with the injection; needle penetration or injection of Barrigel rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. Contraindicated in prostate cancer patients with clinical stage T4 disease. Individual results may vary. Visit barrigel.com<\/a>.<\/p>\n \nCaution: Federal (USA) law restricts this device to sale by or on the order of a physician.<\/p>\n About Interventional Urology Forward-Looking Statements Barrigel, Deflux, and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and\/or other countries. \u00a9 2026 Teleflex Incorporated. All rights reserved. APM1495A<\/i><\/p>\n \n*Studies sponsored by Teleflex.<\/p>\n \n**Drs. Chughtai and King are paid consultants of Teleflex<\/p>\n \n\u2020No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study<\/p>\n References<\/b><\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260521235608\/en\/<\/a><\/span><\/p>\n
\nTeleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift\u2122 System and Barrigel\u2122 rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innovations help urologists treat medical needs while ensuring patients can recover and maintain their quality of life long after treatment.<\/p>\n\n
\n
\n
<\/b>The UroLift\u2122 System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift\u2122 System permanent implants, which can be delivered during an outpatient procedure,3<\/sup> relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift\u2122 System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.4,5 <\/sup>It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.\u2020<\/sup><\/b>6-7<\/sup> A study conducted over five years showed a low retreatment rate of about 2 to 3 percent per year, or a total of 13.6 percent over the course of the study, demonstrating UroLift\u2122 System durability.8 <\/sup>Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.9 <\/sup>Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift\u2122 System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. More than 500,000 men have been treated with the UroLift\u2122 System in select markets worldwide.10<\/sup> Learn more at www.UroLift.com<\/a>.<\/p>\n
\n
<\/strong>The UroLift\u2122 System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 45 years or older with prostates \u2264100 cc. Contraindicated in men with current gross hematuria, urinary tract infection, urinary incontinence due to incompetent sphincter, and urethral conditions that prevent device insertion. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. Visit urolift.com.<\/p>\n
\n
<\/strong>Barrigel\u2122 rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.11 <\/sup>Barrigel\u2122 rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).12<\/sup><\/p>\n
\n
<\/b>Barrigel\u2122 rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, the intent is to reduce the radiation dose delivered to the anterior rectum. It is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient\u2019s body over time.<\/p>\n
\n
<\/b>The Interventional Urology Business Unit is leading in prostate health by advancing clinical evidence, elevating education, and supporting physicians and patients. Our portfolio includes Barrigel\u2122 rectal spacer for men seeking to reduce rectal side effects associated with prostate cancer radiation therapy, the UroLift\u2122 System for men suffering from BPH symptoms, and Deflux\u2122 injectable gel for children with grades II-V vesicoureteral reflux (VUR).<\/p>\n
\n
<\/b>Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.<\/p>\n\n
<\/p>\n